text: Conclusions and Relevance Treatment with an LED showed a trend in favor of clinically important PASI improvement and a significant reduction in DLQI in overweight patients with psoriasis.
  Psoriasis is a chronic inflammatory skin disease with a prevalence of about 2% in Northern Europe and North America.1-3 Psoriasis is associated with an increased prevalence of traditional cardiovascular risk factors, such as diabetes, arterial hypertension, and hyperlipidemia, and an increased risk of myocardial infarction.4-6 In addition, epidemiological studies have established that psoriasis is associated with obesity and that increased adiposity and weight gain are risk factors for incident psoriasis.6-15 Like psoriasis, obesity is accompanied by low-grade systemic inflammation, and, theoretically, obesity-induced proinflammatory mechanisms may exacerbate psoriatic lesions in overweight patients with psoriasis.16 At present, the role of weight loss as a treatment for psoriasis in obese patients is unclear, but it is reasonable to assume that weight loss in such patients may reduce the obesity-induced inflammation, which may in turn improve the skin disease. Indeed, data from case reports of obese patients with psoriasis undergoing weight reduction surgery indicate that psoriasis may improve with weight loss, although in 1 reported case it actually became worse.17-22